Skip to Content
Merck
CN

Affective disorder and hyperandrogenism.

Recent patents on endocrine, metabolic & immune drug discovery (2012-12-04)
Celen Zerouni, Elaine Kummerow, Mariflor Martinez, Ana Diaz, Uribe Ezequiel, Richard Wix-Ramos
ABSTRACT

A 40-year-old female patient with bipolar disorder and premenstrual dysphoric disorder did not present any physical evidence of virilization, treated with quetiapine and lithium carbonate. Laboratory testing showed evidence of hyperandrogenism (Testosterone levels 88.5ng/dL). After control, testosterone levels were normal (free testosterone 0.20 pg/ml, total testosterone 27.90ng/dl), as free thyroxine levels decreased (T4 0.83ng/dl) and increased progesterone levels (progesterone 3.80ng/ml). We consider an association between increased androgenic hormone levels in women, quetiapine and lithium carbonate treatment as well as the presence of an affective disorder and premenstrual dysphoric disorder. Some relevant patents are also outlined in this review.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Lithium carbonate, 99.999% trace metals basis
Sigma-Aldrich
Lithium carbonate, 99.997% trace metals basis
Sigma-Aldrich
Lithium carbonate, ACS reagent, ≥99.0%
Sigma-Aldrich
Lithium carbonate, puriss. p.a., ACS reagent, ≥99.0% (T)